Merck HIV microbicide candidate
Published by AWills March 16th, 2008 in Intellectual Property, Drug Development, HIV/AIDS“Microbicide Developer Receives License for Novel HIV Microbicide Candidate from Merch & Co., Inc.,” International Partnership for Microbicides Press Release, 11 March 2008.
Merck has agreed to provide a full royalty-free license for L’644, a gp41 fusion inhibitor, to the International Partnership for Microbicides (IPM) for development as a potential vaginal microbicide for women in developing countries. Delivery methods under consideration are gels, films or vaginal rings. It’s the sixth drug to be tested by IPM in public-private partnerships with major pharmaceutical companies. Others include a CCR5 blocker by Bristol-Myers Squibb, Merck’s L’167/CMPD167, Pfizer’s maraviroc, Gilead Sciences‘ tenofovir, and Tibotec Pharmaceuticals‘ dapivirine. Dapivirine is expected to enter Phase III clinical trials in 2009.
No Responses to “Merck HIV microbicide candidate”
Please Wait
Leave a Reply
You must log in to post a comment.